This site contains promotional material

Prescribing Information SmPC

THINK MLD, TEST EARLY, REFER URGENTLY AND SCREEN SIBLINGS

Every day counts with MLD

Libmeldy: Ex vivo autologous HSC gene therapy for early-onset MLD

Libmeldy is an autologous haematopoietic stem cell (HSC) gene therapy product for early-onset MLD made specifically for each patient using the patient’s own blood stem cells.1

Abbreviations
ARSA: arylsulfatase A; cDNA: complementary DNA; HSC: haematopoietic stem cell; MLD: metachromatic leukodystrophy

For any medical questions, please contact medinfo@orchard-tx.com

▼ This medicinal product is subject to additional monitoring.
Healthcare professionals are asked to report any suspected adverse events. Further information about local reporting details can be found in Section 4.8 of the Summary of Product Characteristics.

Please also report any adverse events to Orchard Therapeutics at: drugsafety@orchard-tx.com

References

  1. Libmeldy, Summary of Product Characteristics.
  2. Rosenberg JB, et al. J Neurosci Res 2016; 94(11): 1169-1179.